Next-Generation Flagellin-Based Vaccines and Immunotherapies
Legal Citation
Summary of the Inventive Concept
The present inventive concept discloses a new generation of flagellin-based vaccines and immunotherapies that leverage advanced biotechnology tools, machine learning algorithms, and nanoparticle-based adjuvants to provide enhanced immune responses, personalized treatments, and targeted therapies against bacterial infections.
Background and Problem Solved
The original patent disclosed flagellin polypeptides from Enterococcus gallinarum for treating diseases, but it had limitations in terms of immune response stimulation, specificity, and adaptability to different bacterial strains. The present inventive concept addresses these limitations by introducing recombinant flagellin polypeptides with modified domains, nanoparticle-based adjuvants, and machine learning algorithms for personalized immunotherapy.
Detailed Description of the Inventive Concept
The new claims encompass a range of innovative approaches, including the use of recombinant flagellin polypeptides with engineered D0 domains for enhanced TLR5 recognition, personalized immunotherapy systems that utilize genomic information and machine learning algorithms to predict optimal flagellin polypeptide sequences, and modular platforms for developing flagellin-based vaccines with interchangeable modules for generating recombinant polypeptides and formulating them with various adjuvants and delivery systems.
Novelty and Inventive Step
The new claims introduce several novel and non-obvious elements, including the use of nanoparticle-based adjuvants, machine learning algorithms for personalized immunotherapy, and modular platforms for developing flagellin-based vaccines. These elements provide a significant departure from the original patent and offer a new generation of flagellin-based vaccines and immunotherapies with enhanced efficacy and adaptability.
Alternative Embodiments and Variations
Other embodiments of the inventive concept could include the use of different types of adjuvants, such as liposomes or emulsions, or alternative machine learning algorithms for predicting optimal flagellin polypeptide sequences. Additionally, the modular platform could be adapted for use with different bacterial strains or diseases, providing a flexible and scalable approach to vaccine development.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the vaccine and immunotherapy markets, particularly in the context of bacterial infections. The ability to provide personalized and targeted therapies could revolutionize the field of immunotherapy and provide new opportunities for pharmaceutical companies, biotechnology startups, and research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/09 |
| A | A61 | A61K35/744 |
| A | A61 | A61K2039/585 |
| A | A61 | A61P37/04 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunology, microbiology, and biotechnology, specifically focused on bacterial flagellin-based vaccine development and immunotherapeutic strategies. Requires advanced knowledge of protein engineering, immunological mechanisms, and molecular biology techniques
Person of Ordinary Skill (PHOSITA) Profile
A researcher with a PhD in microbiology or immunology, experienced in protein engineering, vaccine development, and understanding of toll-like receptor interactions. Familiar with recombinant protein techniques, machine learning applications in biotechnology, and adjuvant design
Obviousness Rationale
A person skilled in the art would recognize that the PTD represents predictable extensions of the source patent's core concept of Enterococcus flagellin polypeptides as immunological agents. The variations introduce standard biotechnological approaches like machine learning, nanoparticle adjuvants, and modular vaccine platforms that would be considered routine optimization strategies in the field of bacterial vaccine development.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,614 |
|---|---|
| Title | Enterococcus gallinarum flagellin polypeptides |
| Assignee(s) | CJ BIOSCIENCE, INC. |